Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Change in Cash (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Change in Cash for 15 consecutive years, with -$14.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash fell 774.07% to -$14.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$7.2 million, a 155.19% decrease, with the full-year FY2024 number at -$206000.0, up 91.31% from a year prior.
  • Change in Cash was -$14.3 million for Q3 2025 at NovaBay Pharmaceuticals, down from -$3.1 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $8.0 million in Q1 2025 to a low of -$14.3 million in Q3 2025.
  • A 5-year average of -$974368.4 and a median of -$942000.0 in 2023 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: plummeted 1327.27% in 2023, then skyrocketed 714.92% in 2025.
  • NovaBay Pharmaceuticals' Change in Cash stood at -$1.5 million in 2021, then surged by 219.82% to $1.8 million in 2022, then tumbled by 125.85% to -$472000.0 in 2023, then skyrocketed by 554.87% to $2.1 million in 2024, then tumbled by 764.65% to -$14.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Change in Cash are -$14.3 million (Q3 2025), -$3.1 million (Q2 2025), and $8.0 million (Q1 2025).